Bioprofarma Bagó is pleased to present the launch of the product NILTARA® nilotinib, for its Hematology Line. This new product has been approved by ANMAT for the treatment of: Adult and pediatric patients with Philadelphia chromosome-positive chronic myeloid leukemia (CML), recently diagnosed, in chronic phase; Adult patients with Philadelphia chromosome-positive CML in chronic phase and accelerated phase, […]

Bioprofarma Bagó replaces TARGRETIN® with IMPILO®bexarotene.

November 8-10, the XXVI Argentine and International Congress of Clinical Oncology 2023 was held at La Rural, in the City of Buenos Aires, and Bioprofarma Bago was there.